Kamna Jhamb, Founder at Zentra Partners, shared a post on LinkedIn:
“As ADCs reach frontline setting in breast cancer treatment and patients and physicians have access to multiple ADCs drugs, we indeed need to increase our understanding of sequencing strategies.
Thanks Dr Paolo Tarantino and your team for carrying out this study!”
Title: Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
Authors: Paolo Tarantino, Do Lee, Julia Foldi, Pamela R Soulos, Cary P Gross, Tess O’Meara, Thomas Grinda, Stefania Morganti, Adrienne G Waks, Eric P Winer, Nancy U Lin, Ian E Krop, Sara M Tolaney, Sarah Sammons, Maryam Lustberg
Read The Full Article at Journal of the National Cancer Institute.
More posts featuring Paolo Tarantino.